Today: 30 June 2026
Browse Category

NYSE:NVO 8 November 2025 - 18 December 2025

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly and Company finished Thursday’s session higher and held those gains in after-hours trading, as investors digested fresh late-stage data for its oral obesity candidate orforglipron—and weighed a second, potentially market-moving theme: pricing pressure and affordability initiatives. As of early evening after the closing bell, LLY was little changed in after-hours trading at $1,057.26, after closing the regular session at $1,056.88. Investing.com
18 December 2025
···
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: the EU regulator’s support for a higher-dose Wegovy, the long-telegraphed India launch of Ozempic at a sharply lower price point, and the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand beyond obesity/diabetes into MASH. Reuters+2Reuters+2
14 December 2025
····
Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk shares are trying to stabilise after a bruising November as fresh obesity‑drug data, a higher‑dose Wegovy filing and new analyst calls collide with lingering worries about growth and competition. Novo Nordisk’s U.S.-listed ADRs are changing hands around $49.25, up roughly 1% on the day, after trading between $48.35 and $49.75 in Friday’s session. Intraday volume is a little over 6.7 million shares, in line with recent elevated activity.
28 November 2025
·
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin. As of 20:48 UTC on 26 November 2025, Novo Nordisk’s U.S.-listed ADRs traded at $48.79, up about 3.7% on the day, with intraday trading between $46.79 and $49.02 and volume near 15 million shares.
26 November 2025
···
US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

As Wall Street wakes up on Monday, November 24, 2025, U.S. stock futures are pointing to a positive open for the Dow Jones, S&P 500 and Nasdaq, kicking off a holiday‑shortened Thanksgiving week. Gains are being driven by rising expectations of a December Federal Reserve rate cut, a rebound in bitcoin and crypto‑linked stocks, and heavy pre‑market trading in big tech and AI names — even as November remains one of the roughest months of the year for equities so far. The Economic Times+3Investopedia+3Simply Wall St+3 At the same time, a failed Alzheimer’s trial from Novo Nordisk, renewed U.S.–EU trade tensions and cautious optimism around Ukraine peace talks are shaping sector‑specific moves in healthcare, defense, industrials and tech. Investopedia+1
25 November 2025
···
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen Inc. shares surged to fresh 52‑week highs on Monday, November 24, 2025, as investors reacted to a high‑profile Alzheimer’s drug failure at Novo Nordisk and a new immunology partnership with Dayra Therapeutics. By the closing bell, BIIB stock finished at $177.42, up about 1.2% from Friday’s close of $175.30. The stock traded as high as $185.17 intraday, with volume just over 2.0 million shares, roughly in line with its recent average. StockAnalysis
24 November 2025
··
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion. In Copenhagen, Novo Nordisk’s B‑shares finished the session around DKK 305, down nearly 3% and extending a steep slide that has left the stock down about 45% year‑to‑date. Investing.com+1
21 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker. On Thursday, November 20, 2025, Novo Nordisk’s U.S.-listed ADR is trading around $49, roughly in line with Wednesday’s close, after a 3% rebound the previous day.StockInvest+1
20 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Published November 18, 2025 Summary: Novo Nordisk remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its ConvaTec stake in London. U.S.-listed shares were modestly lower intraday as investors weighed near‑term pricing pressure against potential volume gains and ongoing governance/pipeline developments. Reuters+2NovoCare+2
18 November 2025
··
LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss market This morning, LifeMD, Inc. unveiled what it calls the lowest cash‑pay pricing available nationwide for the GLP‑1 weight‑loss drugs Wegovy and Ozempic, in continued collaboration with Novo Nordisk. MarketScreener+3GlobeNewswire+3Quiver Quantitative+3
17 November 2025
··
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio, Inc. is at the center of one of biotech’s biggest shake‑ups of 2025. After releasing mixed early data from its lead RNA‑editing program, KRRO‑110, the company has announced deep layoffs, a strategic pivot in its pipeline and a 12‑month pause in its high‑profile collaboration with Novo Nordisk. The stock has responded with a brutal collapse. As of Thursday, 13 November 2025, here’s a full rundown of everything that has hit the tape around Korro Bio today and what it could mean for KRRO shareholders.
13 November 2025
··
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement:
10 November 2025
····
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck a distribution pact in India to sell a new branded version of its semaglutide weight‑loss shot. Reuters+3Reuters+3Reuters+3
10 November 2025
··
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1
8 November 2025
···
1 … 3 4 5 6 7

Stock Market Today

  • Cramer's 10 Big Movers for June 30
    June 30, 2026, 9:20 AM EDT. Jim Cramer flagged 10 top market moves for Tuesday, June 30. S&P 500 and Nasdaq futures were flat as both indexes looked set for their best quarters since Q2 2020, up about 14% and 20%. Comcast jumped after Deutsche Bank upgraded the stock following its NBCUniversal spin-off. Applied Materials and Lam Research both got price target hikes because of ongoing chip shortages. Wells Fargo lifted its price target on AMD as the company stands out in CPU and GPU spaces. Morgan Stanley raised Alphabet to an upgrade on optimism over Google Cloud. Piper Sandler put a buy on Capital One, though with some caution. Logitech got a downgrade on weaker demand. AeroVironment soared more than 30% after drone results beat expectations. The moves point to selective strength in tech and financial names.
Go toTop